Actinium Pharmaceuticals (ATNM) Free Cash Flow (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Free Cash Flow of -$5.9 million for Q1 2026, up 22.47% year-over-year from -$4.8 million in Q1 2025, and down 11.02% quarter-over-quarter from -$5.3 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Free Cash Flow (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Free Cash Flow for 17 consecutive years, with -$5.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 22.47% year-over-year to -$5.9 million; the TTM figure through Mar 2026 stood at -$22.9 million (up 31.24% YoY), while the FY2025 annual figure was -$24.7 million, up 25.39% from the prior year.
- Free Cash Flow eased to -$5.9 million in Q1 2026 per ATNM's latest filing, from -$5.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $27.6 million in Q2 2022 and bottomed at -$15.2 million in Q1 2023.
- Historically, Free Cash Flow has averaged -$6.0 million across 5 years, with a median of -$7.4 million in 2024.
- Annual changes were most pronounced in 2022 — Free Cash Flow soared 695.22% — and 2023, when it plunged 161.8%.
- Actinium Pharmaceuticals' Free Cash Flow stood at -$7.8 million in 2022, then increased by 3.9% to -$7.5 million in 2023, then rose by 23.22% to -$5.8 million in 2024, then climbed by 8.03% to -$5.3 million in 2025, then decreased by 11.02% to -$5.9 million in 2026.
- Business Quant data shows ATNM's Free Cash Flow at -$5.9 million in Q1 2026, -$5.3 million in Q4 2025, and -$6.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | -5.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.66 Mn |
| Jun 30, 2026 | -5.66 Mn |
| Mar 31, 2026 | -5.87 Mn |
| Mar 31, 2026 | -5.87 Mn |
| Dec 31, 2025 | -5.29 Mn |
| Dec 31, 2025 | -5.29 Mn |
| Sep 30, 2025 | -6.33 Mn |
| Sep 30, 2025 | -6.33 Mn |
| Jun 30, 2025 | -5.39 Mn |
| Jun 30, 2025 | -5.39 Mn |
| Mar 31, 2025 | -7.57 Mn |
| Mar 31, 2025 | -7.57 Mn |
| Dec 31, 2024 | -5.75 Mn |
| Dec 31, 2024 | -5.75 Mn |
| Sep 30, 2024 | -11.98 Mn |
| Sep 30, 2024 | -11.98 Mn |
| Jun 30, 2024 | -7.97 Mn |
| Jun 30, 2024 | -7.97 Mn |
| Mar 31, 2024 | -7.39 Mn |
| Mar 31, 2024 | -7.39 Mn |